Literature DB >> 11687462

Circulating inflammatory mediators in patients with fever: predicting bloodstream infection.

A B Groeneveld1, A W Bossink, G J van Mierlo, C E Hack.   

Abstract

The systemic host response to microbial infection involves clinical signs and symptoms of infection, including fever and elevated white blood cell (WBC) counts. In addition, inflammatory mediators are released, including activated complement product C3a, interleukin 6 (IL-6), and the acute-phase reactant secretory phospholipase A(2) (sPLA(2)). To compare the value of the latter with the former in predicting (the degree of) microbial infection at the bedside, we determined clinical variables and took blood samples daily for 3 consecutive days in 300 patients with a new fever (>38.0 degrees C rectally or >38.3 degrees C axillary). Microbiological culture results for 7 days after inclusion were collected. Patients were divided into clinical and microbial categories: those without and with a clinical focus of infection and those with negative cultures, with positive local cultures or specific stains for fungal (n = 13) or tuberculous infections (n = 1), and with positive blood cultures, including one patient with malaria parasitemia. The area under the curve (AUC) of the receiver operating characteristic (ROC) for prediction of positive cultures was 0.60 (P < 0.005) for peak temperature and 0.59 (P < 0.01) for peak WBC count, 0.60 (P < 0.005) for peak C3a, 0.63 (P < 0.001) for peak IL-6, and 0.61 (P < 0.001) for peak sPLA(2). The AUC under the ROC curve for prediction of positive blood cultures was 0.68 (P < 0.001) for peak temperature and 0.56 for peak WBC count (P < 0.05). The AUC for peak C3a was 0.69, that for peak IL-6 was 0.70, and that for sPLA(2) was 0.67 (for all, P < 0.001). The degree of microbial invasion is thus a major determinant of the clinical and inflammatory host response in patients with fever. Moreover, circulating inflammatory mediators such as C3a and IL-6 may help to predict positive blood cultures, together with clinical signs and symptoms of the host response to microbial infection, even before culture results are available. This may help in the designing of entry criteria for therapeutic intervention studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687462      PMCID: PMC96248          DOI: 10.1128/CDLI.8.6.1189-1195.2001

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  33 in total

Review 1.  American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.

Authors: 
Journal:  Crit Care Med       Date:  1992-06       Impact factor: 7.598

2.  Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis.

Authors:  C E Hack; J H Nuijens; R J Felt-Bersma; W O Schreuder; A J Eerenberg-Belmer; J Paardekooper; W Bronsveld; L G Thijs
Journal:  Am J Med       Date:  1989-01       Impact factor: 4.965

3.  Endogenous mediators in emergency department patients with presumed sepsis: are levels associated with progression to severe sepsis and death?

Authors:  C A Terregino; B L Lopez; D J Karras; A J Killian; G K Arnold
Journal:  Ann Emerg Med       Date:  2000-01       Impact factor: 5.721

4.  Cytokine serum level during severe sepsis in human IL-6 as a marker of severity.

Authors:  P Damas; D Ledoux; M Nys; Y Vrindts; D De Groote; P Franchimont; M Lamy
Journal:  Ann Surg       Date:  1992-04       Impact factor: 12.969

5.  Prediction of microbial infection and mortality in medical patients with fever: plasma procalcitonin, neutrophilic elastase-alpha1-antitrypsin, and lactoferrin compared with clinical variables.

Authors:  A W Bossink; A B Groeneveld; L G Thijs
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

6.  Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6.

Authors:  O Selberg; H Hecker; M Martin; A Klos; W Bautsch; J Köhl
Journal:  Crit Care Med       Date:  2000-08       Impact factor: 7.598

7.  Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans.

Authors:  A S Dofferhoff; V J Bom; H G de Vries-Hospers; J van Ingen; J vd Meer; B P Hazenberg; P O Mulder; J Weits
Journal:  Crit Care Med       Date:  1992-02       Impact factor: 7.598

8.  High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group.

Authors:  T Calandra; J Gerain; D Heumann; J D Baumgartner; M P Glauser
Journal:  Am J Med       Date:  1991-07       Impact factor: 4.965

9.  Fever in hospitalized patients. With special reference to the medical service.

Authors:  J E McGowan; R C Rose; N F Jacobs; D R Schaberg; R W Haley
Journal:  Am J Med       Date:  1987-03-23       Impact factor: 4.965

10.  Increased plasma levels of interleukin-6 in sepsis.

Authors:  C E Hack; E R De Groot; R J Felt-Bersma; J H Nuijens; R J Strack Van Schijndel; A J Eerenberg-Belmer; L G Thijs; L A Aarden
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

View more
  10 in total

1.  Circulating inflammatory mediators during start of fever in differential diagnosis of gram-negative and gram-positive infections in leukopenic rats.

Authors:  Eva Tavares; Rosario Maldonado; Maria L Ojeda; Francisco J Miñano
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

Review 2.  Brief report: incidence, etiology, risk factors, and outcome of hospital-acquired fever: a systematic, evidence-based review.

Authors:  Daniel R Kaul; Scott A Flanders; James M Beck; Sanjay Saint
Journal:  J Gen Intern Med       Date:  2006-11       Impact factor: 5.128

3.  Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults.

Authors:  Daniel Molano Franco; Ingrid Arevalo-Rodriguez; Marta Roqué I Figuls; Nadia G Montero Oleas; Xavier Nuvials; Javier Zamora
Journal:  Cochrane Database Syst Rev       Date:  2019-04-30

4.  Usefulness of a real-time bowel sound analysis system in patients with severe sepsis (pilot study).

Authors:  Junko Goto; Kenichi Matsuda; Norikazu Harii; Takeshi Moriguchi; Masahiko Yanagisawa; Osamu Sakata
Journal:  J Artif Organs       Date:  2014-11-06       Impact factor: 1.731

5.  Sedimentation characteristics of leucocytes can predict bacteraemia in critical care patients.

Authors:  L Bogar; Z Molnar; P Kenyeres; P Tarsoly
Journal:  J Clin Pathol       Date:  2006-03-13       Impact factor: 3.411

6.  Mannan binding lectin in febrile adults: no correlation with microbial infection and complement activation.

Authors:  A N Tacx; A B J Groeneveld; M H Hart; L A Aarden; C E Hack
Journal:  J Clin Pathol       Date:  2003-12       Impact factor: 3.411

7.  Cytokines regulate complement receptor immunoglobulin expression and phagocytosis of Candida albicans in human macrophages: A control point in anti-microbial immunity.

Authors:  Usma Munawara; Annabelle G Small; Alex Quach; Nick N Gorgani; Catherine A Abbott; Antonio Ferrante
Journal:  Sci Rep       Date:  2017-06-22       Impact factor: 4.379

8.  Euthermic endocarditis.

Authors:  Daniel C DeSimone; Larry M Baddour; Brian D Lahr; Heath H Chung; Walter R Wilson; James M Steckelberg
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

9.  Boron Induces Lymphocyte Proliferation and Modulates the Priming Effects of Lipopolysaccharide on Macrophages.

Authors:  Indusmita Routray; Shakir Ali
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

10.  DPIE [2-(1,2-diphenyl-1H-indol-3-yl)ethanamine] Augments Pro-Inflammatory Cytokine Production in IL-1β-Stimulated Primary Human Oral Cells.

Authors:  Sun-Hee Ahn; Jin-Kyung Lee; Nam Doo Kim; Seok-Ho Kim; Sunwoo Lee; Seunggon Jung; Kee-Oh Chay; Tae-Hoon Lee
Journal:  Int J Mol Sci       Date:  2018-06-22       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.